Overview

Dose Range Study of CD5789 in Acne Vulgaris

Status:
Completed

Trial end date:
2014-06-12

Target enrollment:

Participant gender:

Summary

To assess the efficacy and safety of different concentrations of CD5789 cream in participants with acne vulgaris for the purpose of dose identification.

Phase:

Phase 2

Details

Lead Sponsor:

Galderma
Galderma R&D

Treatments:

Nicotinic Acids
Tazarotene
Trifarotene